Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole

• Status: Recruiting
• Trial end date: 2025-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to compare two FDA approved medications (aripiprazole and risperidone) for the treatment of behavioral dysregulation in children with autism spectrum disorders. This trial, done in the context of routine clinical care, will seek to evaluate whether aripiprazole or risperidone is associated with more weight gain in children.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vanderbilt University Medical Center
• Treatments: Aripiprazole; Risperidone

Criteria

Inclusion Criteria:

• age 17 years and young

• diagnosed with autism

• have behavior problems

• seen in Vanderbilt clinic

• naïve to atypical antipsychotics

Exclusion Criteria:

• 18 years or older

• history of atypical antipsychotic use

• not diagnosed with autism